Morfina 1% Braun (Morphine Hydrochloride Trihydrate)

Morphine, the active ingredient in Morfina 1% Braun, is an opioid analgesic presented as a 1% (10 mg/mL) injectable solution for epidural, intramuscular, and intrathecal use. It provides relief for severe acute pain, postoperative pain, cancer‑related pain, and labor analgesia in adult patients.

GNH USA supplies Morfina 1% Braun as a licensed, GDP‑compliant international pharmaceutical product serving hospitals, oncology centres, and clinics worldwide, with a focus on reliable supply chains and timely delivery to meet clinical demand.

Morphine, an opioid analgesic, is employed to manage pain by acting on central nervous system pathways.

- Severe acute pain: provides rapid and potent relief of intense, short‑term pain episodes. - Post‑operative pain: reduces discomfort following surgical procedures, facilitating recovery and mobilization. - Cancer pain: controls persistent malignant pain, improving quality of life for oncology patients. - Labor analgesia: offers effective pain relief during childbirth while maintaining maternal safety.

Morphine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: feeling of sickness that may lead to vomiting. - Constipation: reduced bowel movements and hard stools. - Drowsiness: increased sleepiness and reduced alertness. - Itching (pruritus): skin irritation often localized. - Vomiting: expulsion of stomach contents, often following nausea. - Dry mouth: reduced salivation causing discomfort.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure causing dizziness or fainting. - Anaphylactic reaction: sudden severe allergic response requiring immediate medical attention.

When using morphine injectable solutions, several precautions should be observed to ensure patient safety. - Assess respiratory function: monitor breathing rate, oxygen saturation, and signs of hypoventilation. - Evaluate renal and hepatic function: adjust therapy in patients with impairment to avoid accumulation. - Use caution in elderly: increased sensitivity to central nervous system effects may require lower doses. - Avoid concurrent CNS depressants: combined use with benzodiazepines or barbiturates can enhance sedation. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Morphine can interact with other medicines, altering its effects or increasing risk of adverse events.

Major Interactions (Avoid): - Other opioids: additive respiratory depression and profound sedation. - Benzodiazepines or barbiturates: synergistic central nervous system depression. - MAO inhibitors: risk of serotonin syndrome and hypertensive crisis.

Moderate Interactions (Monitor Closely): - CNS depressants (antihistamines, muscle relaxants): may increase drowsiness. - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): can raise morphine plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce analgesic efficacy.